US Edition
Jupiter spotlights critical advancement of JOTROL v conventional resveratrol - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Jupiter spotlights critical advancement of JOTROL v conventional resveratrol - BioTuesdays
Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the critical advancement of its proprietary resveratrol platform, JOTROL, compared to conventional resveratrol formulations, citing breakthrough bioavailability and central nervous system- (CNS) targeted science. The company lists key differentiators, including: Approximately nine times higher bioavailability at peak plasma concentration versus naïve resveratrol No gastrointestinal (GI) side …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
